CXCL8 and urinary bladder cancer: Moreover, after extracting RNA and protein from bladder cancer cells treated with and without CM, we found that the expression of E-cadherin significantly decreased in bladder cancer cells treated with CM, an effect that could be resisted using an anti-CXCL8 neutralizing antibody (Among bladder cancer cells, T24 has the highest degree of malignancy, which may lead to low or even no expression of E-cadherin in T24).